These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 9183245)
41. Dexfenfluramine, fenfluramine, and phentermine for the treatment of morbid obesity. Torretta LK J Am Acad Nurse Pract; 1997 Aug; 9(8):389-94, quiz 395-7. PubMed ID: 9325813 [No Abstract] [Full Text] [Related]
42. Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine. Glatz AC; Ehrlich M; Bae RS; Clarke MJ; Quinlan PA; Brown EC; Rada P; Hoebel BG Pharmacol Biochem Behav; 2002; 71(1-2):197-204. PubMed ID: 11812523 [TBL] [Abstract][Full Text] [Related]
43. A close look at fenfluramine and dexfenfluramine. Vivero LE; Anderson PO; Clark RF J Emerg Med; 1998; 16(2):197-205. PubMed ID: 9543401 [TBL] [Abstract][Full Text] [Related]
44. Primary pulmonary hypertension and long-term use of appetite suppressants. Sztuke-Fournier A CMAJ; 1997 Jan; 156(1):89-90, 93-4. PubMed ID: 9006574 [No Abstract] [Full Text] [Related]
45. From the Food and Drug Administration. Nightingale SL JAMA; 1996 Jul; 276(1):14. PubMed ID: 8667525 [No Abstract] [Full Text] [Related]
47. Hypotensive effect of fenfluramine in the treatment of obesity. Practitioner; 1971 Jul; 207(237):101-5. PubMed ID: 5557039 [No Abstract] [Full Text] [Related]
48. The age-adjusted mortality rate from primary pulmonary hypertension, in age range 20 to 54 years, did not increase during the years of peak "phen/fen" use. Rothman RB Chest; 2000 Nov; 118(5):1516-7. PubMed ID: 11083718 [No Abstract] [Full Text] [Related]
49. The serotonergic appetite suppressant fenfluramine. Reappraisal and rejection. Curzon G; Gibson EL Adv Exp Med Biol; 1999; 467():95-100. PubMed ID: 10721044 [TBL] [Abstract][Full Text] [Related]
50. Treatment of refractory obesity with fenfluramine. Munro JF; Seaton DA; Duncan LJ Br Med J; 1966 Sep; 2(5514):624-5. PubMed ID: 5331182 [No Abstract] [Full Text] [Related]
51. [The French are wary of their drugs]. Nau JY Rev Med Suisse; 2011 May; 7(296):1170-1. PubMed ID: 21728251 [No Abstract] [Full Text] [Related]
52. Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts. Tellier P Ann Med Interne (Paris); 2001 Nov; 152(7):429-36. PubMed ID: 11965083 [TBL] [Abstract][Full Text] [Related]
53. Anorectic therapy and valvular heart disease: a reappraisal. Silvestry FE; St John Sutton M Eur Heart J; 1999 Jul; 20(13):917-20. PubMed ID: 10361039 [No Abstract] [Full Text] [Related]
54. Dexfenfluramine for weight gain secondary to psychotropics. Masand PS; Gupta S Depress Anxiety; 1997; 6(3):119-23. PubMed ID: 9442986 [TBL] [Abstract][Full Text] [Related]
55. [The role of anorexigenics in the treatment of obesity]. Laroche C; Boissonnas A Therapie; 1979; 34(2):181-95. PubMed ID: 386556 [No Abstract] [Full Text] [Related]
56. With new diet drug, challenge is weighing patient demand and potential benefit. Jones L Ann Intern Med; 1996 Aug; 125(4):I58. PubMed ID: 9446497 [No Abstract] [Full Text] [Related]
57. Serotonergic agents in the treatment of hypothalamic obesity syndrome: a case report. Jordaan GP; Roberts MC; Emsley RA Int J Eat Disord; 1996 Jul; 20(1):111-3. PubMed ID: 8807359 [TBL] [Abstract][Full Text] [Related]
58. A comparative trial of fenfluramine and diethylpropion in obese, hypertensive patients. Follows OJ Br J Clin Pract; 1971 May; 25(5):236-8. PubMed ID: 4931755 [No Abstract] [Full Text] [Related]
59. Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography. Roldan CA; Gelgand EA; Decker P; Prasad A; Shively BK Am J Cardiol; 2002 Dec; 90(11):1269-73. PubMed ID: 12450616 [No Abstract] [Full Text] [Related]
60. Aminorex to fen/phen: an epidemic foretold. Fishman AP Circulation; 1999 Jan 5-12; 99(1):156-61. PubMed ID: 9884392 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]